Debut de colitis ulcerosa en contexto de tratamiento con secukinumab: ¿los anti-IL-17A pueden ser un factor desencadenante para la aparición de la enfermedad inflamatoria intestinal?

Rodríguez Moncada, Rafael; Vázquez Morón, Juan María; Pallarés Manrique, Héctor.
Rev. esp. enferm. dig ; 111(9): 720-721, sept. 2019. tab
Artículo en Español | IBECS (España) | ID: ibc-190360

Documentos relacionados

  1. Paradoxical gastrointestinal effects of interleukin-17 blockers.
  2. Some Drugs Have Two Faces: Paradoxical Colitis in a Patient with Psoriatic Arthritis Previously Treated with Etanercept and IL-17 Inhibitors.
  3. The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?
  4. Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review.
  5. A case of multifocal motor neuropathy after initiation of ixekizumab for psoriatic arthopathy.
  6. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
  7. Psoriasis vulgaris patient with psoriatic arthritis managed with interleukin-17A inhibitor: Balancing benefits and adverse effects.
  8. Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
  9. Combination Therapy With Tofacitinib and IL-12/23, IL-23, or IL-17A Inhibition for the Treatment of Refractory Psoriatic Arthritis: A Case Series.
  10. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.